Humacyte, Inc. priced public offering of 25 million shares at $2 each

From GlobeNewswire: 2025-03-25 20:35:00

Humacyte, Inc. (Nasdaq: HUMA) announced a public offering of 25,000,000 shares of common stock at $2.00 per share, expected to yield $50 million in gross proceeds. The offering, expected to close on March 27, 2025, includes an option for underwriters to purchase an additional 3,750,000 shares. Proceeds will fund the commercialization of SYMVESS™ in vascular trauma, product development, and general corporate purposes. Humacyte develops bioengineered human tissues and is advancing clinical trials for its vascular applications. The company’s ATEVs have received FDA approvals and designations for various medical uses, including vascular trauma and hemodialysis access.



Read more at GlobeNewswire: Humacyte, Inc. Announces Pricing of Public Offering of